Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best.
Explore our pipelineNEUROLOGY PIPELINE - WHOLLY OWNED | ||||
Indication | Preclinical | Phase 1/2 | Pivotal | Partner |
Idiopathic Small Fiber Neuropathy (ST-503) | None |
|||
Prion Disease | None |
|||
Undisclosed neurology target(s) | None |
NEUROLOGY PIPELINE - PARTNERED | ||||
Indication | Preclinical | Phase 1/2 | Pivotal | Partner |
Genentech
![]() |
||||
Undisclosed neurology target
|
Genentech
![]() |
|||
Undisclosed neurology target
|
Astellas
![]() |
|||
Undisclosed neurology target
|
Lilly
|
|||
Alexion
|
||||
Takeda
|
OTHER PROGRAMS | ||||
Indication | Preclinical | Phase 1/2 | Pivotal | Partner |
Hemophilia A (Giroctogene fitelparvovec) |
Pfizer
*until April 21, 2025 |
|||
Fabry Disease (Isaralgagene civaparvovec) | None |